Esomeprazole

證據等級: L5

預測適應症: 10 個

One-Sentence Summary

Esomeprazole is a proton pump inhibitor (PPI) established for treating gastro-oesophageal reflux disease, erosive oesophagitis, peptic ulcer disease and Helicobacter pylori eradication. The TxGNN model predicts it may be effective for Duodenogastric Reflux, but this is currently supported by 0 clinical trials and only 1 general (non-specific) publication, so the evidence base is very thin.

Quick Overview

Item	Content
Original Indication	Not available from ARTG (drug not marketed in Australia); literature indicates broad PPI-class use in GORD, erosive oesophagitis, peptic ulcer disease and H. pylori eradication
Predicted New Indication	Duodenogastric Reflux
TxGNN Prediction Score	99.53%
Evidence Level	L5
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data for this candidate is not currently available (Data Gap DG002). Based on the literature retrieved in this evidence pack, esomeprazole is the S-isomer of omeprazole, part of the proton pump inhibitor (PPI) class, and works by irreversibly inhibiting the H⁺/K⁺-ATPase (“proton pump”) in gastric parietal cells to suppress gastric acid secretion. Its efficacy in gastro-oesophageal reflux disease, erosive oesophagitis, peptic ulcer disease, and NSAID-associated ulcer prevention/healing is well established in the literature returned here (e.g. PMID 18627213, PMID 12093317).

Duodenogastric reflux involves retrograde flow of duodenal contents (bile, pancreatic enzymes) into the stomach, which can coexist with or aggravate acid-related mucosal injury and symptoms that overlap with GORD. Mechanistically, acid suppression by esomeprazole could plausibly reduce the acid component of the mixed reflux injury, which may explain why the TxGNN model links this drug to the disease. However, none of the retrieved evidence directly studies esomeprazole in duodenogastric reflux specifically — the single retrieved publication is a general review of PPI clinical use, not a disease-specific study. The mechanistic rationale is therefore plausible but currently unconfirmed by direct evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
18679668	2008	Review	European Journal of Clinical Pharmacology	General review of PPI clinical use — describes PPIs as first-choice treatment for peptic ulcer, H. pylori infection, gastro-oesophageal reflux disease, NSAID-induced GI lesions, and Zollinger-Ellison syndrome. Does not specifically address duodenogastric reflux.

Australia Market Information

Currently no ARTG entries found. Esomeprazole is recorded as “not marketed” in this evidence pack, with 0 total licences on file.

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information.

(Note: A Blocking data gap exists — DG001, TGA/PI warnings and contraindications have not yet been retrieved. This must be resolved before any safety-related decision can be finalised.)

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction score is high, but there is no clinical trial evidence and only one tangential, non-specific publication for duodenogastric reflux specifically. Combined with the absence of TFDA/TGA safety data (Blocking gap) and the drug’s “not marketed” status in Australia, the evidence does not yet support progression.

To proceed, the following is needed:

Disease-specific clinical or observational studies on esomeprazole for duodenogastric reflux
TGA-approved Product Information / warnings and contraindications (resolves DG001)
Confirmed mechanism of action documentation (resolves DG002)
ARTG registration status confirmation if market entry to Australia is being considered
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.